On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had identified additional candidates through their in silico screening study. In addition to four compounds that target an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15) and one additional core compound that targets the main protease (Mpro) of the virus, Anixa and OntoChem have identified 26 additional compounds targeting Mpro.

The new Mpro compounds were being synthesized,and upon completion evaluated in biological assays.